Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Oral dutasteride 0.5 mg combined with oral minoxidil 2.5 mg is highly effective for male androgenetic alopecia, showing over 60% improvement and 98% stabilization at 6 months, with low adverse event rates. Patients with severe baseline conditions respond better and faster to this treatment.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

A user stopped using minoxidil due to severe side effects and experienced rapid hair loss. They also tried finasteride and dutasteride but faced adverse reactions, leading them to consider accepting hair loss and exploring options like oral minoxidil or a hair transplant.